vs
STANDARD BIOTOOLS INC.（LAB）与Sachem Capital Corp.（SACH）财务数据对比。点击上方公司名可切换其他公司
STANDARD BIOTOOLS INC.的季度营收约是Sachem Capital Corp.的1.6倍（$19.6M vs $12.0M），Sachem Capital Corp.净利率更高（8.3% vs -177.4%，领先185.7%），STANDARD BIOTOOLS INC.同比增速更快（-11.5% vs -18.8%），过去两年STANDARD BIOTOOLS INC.的营收复合增速更高（-12.2% vs -13.4%）
Standard BioTools（原Fluidigm公司）是一家美国生命科学工具企业，主营流式细胞术与组织成像分析用质谱流式系统，以及配套的检测试剂盒与试剂，同时供应自动化基因组分析仪器、各类微流控芯片（又称集成流体电路）及配套试剂耗材，全系列产品及应用场景均可提供定制检测方案与相关服务。
Sachem Head Capital Management是一家总部位于美国纽约市的价值型投资管理公司，由斯科特·弗格森负责运营管理，专注于遵循价值投资理念开展投资管理业务。
LAB vs SACH — 直观对比
营收规模更大
LAB
是对方的1.6倍
$12.0M
营收增速更快
LAB
高出7.4%
-18.8%
净利率更高
SACH
高出185.7%
-177.4%
两年增速更快
LAB
近两年复合增速
-13.4%
损益表 — Q3 FY2025 vs Q3 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $19.6M | $12.0M |
| 净利润 | $-34.7M | $997.0K |
| 毛利率 | 48.5% | — |
| 营业利润率 | -168.5% | -3.1% |
| 净利率 | -177.4% | 8.3% |
| 营收同比 | -11.5% | -18.8% |
| 净利润同比 | -28.8% | 119.7% |
| 每股收益（稀释后） | $-0.09 | $0.00 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收LABSACH
| Q3 25 | $19.6M | $12.0M | ||
| Q2 25 | $21.8M | $10.8M | ||
| Q1 25 | $40.8M | $11.4M | ||
| Q4 24 | — | $10.8M | ||
| Q3 24 | $22.1M | $14.8M | ||
| Q2 24 | $22.5M | $15.1M | ||
| Q1 24 | $45.5M | $16.8M | ||
| Q4 23 | $28.2M | $16.0M |
净利润LABSACH
| Q3 25 | $-34.7M | $997.0K | ||
| Q2 25 | $-33.5M | $1.9M | ||
| Q1 25 | $-26.0M | $904.0K | ||
| Q4 24 | — | $-36.1M | ||
| Q3 24 | $-26.9M | $-5.1M | ||
| Q2 24 | $-45.7M | $-3.1M | ||
| Q1 24 | $-32.2M | $4.7M | ||
| Q4 23 | $-19.8M | $-1.1M |
毛利率LABSACH
| Q3 25 | 48.5% | — | ||
| Q2 25 | 48.8% | — | ||
| Q1 25 | 48.4% | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 54.9% | — | ||
| Q2 24 | 46.1% | — | ||
| Q1 24 | 53.1% | — | ||
| Q4 23 | 47.6% | — |
营业利润率LABSACH
| Q3 25 | -168.5% | -3.1% | ||
| Q2 25 | -118.1% | 9.9% | ||
| Q1 25 | -80.8% | 9.0% | ||
| Q4 24 | — | -131.1% | ||
| Q3 24 | -120.9% | -32.6% | ||
| Q2 24 | -134.5% | -20.6% | ||
| Q1 24 | -132.2% | 25.4% | ||
| Q4 23 | -75.9% | — |
净利率LABSACH
| Q3 25 | -177.4% | 8.3% | ||
| Q2 25 | -153.7% | 17.5% | ||
| Q1 25 | -63.8% | 7.9% | ||
| Q4 24 | — | -335.6% | ||
| Q3 24 | -122.0% | -34.2% | ||
| Q2 24 | -203.3% | -20.2% | ||
| Q1 24 | -70.6% | 27.8% | ||
| Q4 23 | -70.2% | -6.9% |
每股收益（稀释后）LABSACH
| Q3 25 | $-0.09 | $0.00 | ||
| Q2 25 | $-0.09 | $0.02 | ||
| Q1 25 | $-0.07 | $0.00 | ||
| Q4 24 | — | $-0.79 | ||
| Q3 24 | $-0.07 | $-0.13 | ||
| Q2 24 | $-0.12 | $-0.09 | ||
| Q1 24 | $-0.27 | $0.08 | ||
| Q4 23 | $-0.24 | $-0.06 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $129.4M | $12.6M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $399.7M | $175.6M |
| 总资产 | $539.6M | $484.4M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资LABSACH
| Q3 25 | $129.4M | $12.6M | ||
| Q2 25 | $158.6M | $23.5M | ||
| Q1 25 | $150.9M | $25.8M | ||
| Q4 24 | — | $19.6M | ||
| Q3 24 | $210.6M | $7.4M | ||
| Q2 24 | $269.8M | $12.4M | ||
| Q1 24 | $287.1M | $56.8M | ||
| Q4 23 | $51.7M | $50.4M |
总债务LABSACH
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | $230.2M | ||
| Q4 24 | — | $230.2M | ||
| Q3 24 | $55.2M | $264.7M | ||
| Q2 24 | $55.1M | $264.7M | ||
| Q1 24 | $55.0M | $288.4M | ||
| Q4 23 | $63.5M | $288.4M |
股东权益LABSACH
| Q3 25 | $399.7M | $175.6M | ||
| Q2 25 | $424.5M | $177.9M | ||
| Q1 25 | $454.6M | $179.3M | ||
| Q4 24 | — | $181.7M | ||
| Q3 24 | $489.3M | $220.6M | ||
| Q2 24 | $510.3M | $230.2M | ||
| Q1 24 | $577.3M | $237.4M | ||
| Q4 23 | $-148.1M | $230.1M |
总资产LABSACH
| Q3 25 | $539.6M | $484.4M | ||
| Q2 25 | $557.0M | $501.8M | ||
| Q1 25 | $579.6M | $491.4M | ||
| Q4 24 | — | $492.0M | ||
| Q3 24 | $681.5M | $555.5M | ||
| Q2 24 | $708.7M | $586.3M | ||
| Q1 24 | $777.7M | $626.5M | ||
| Q4 23 | $323.1M | $620.9M |
负债/权益比LABSACH
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 1.28× | ||
| Q4 24 | — | 1.27× | ||
| Q3 24 | 0.11× | 1.20× | ||
| Q2 24 | 0.11× | 1.15× | ||
| Q1 24 | 0.10× | 1.21× | ||
| Q4 23 | — | 1.25× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-22.2M | $4.9M |
| 自由现金流经营现金流 - 资本支出 | $-23.1M | — |
| 自由现金流率自由现金流/营收 | -118.1% | — |
| 资本支出强度资本支出/营收 | 4.5% | — |
| 现金转化率经营现金流/净利润 | — | 4.95× |
| 过去12个月自由现金流最近4个季度 | $-111.1M | — |
8季度趋势，按日历期对齐
经营现金流LABSACH
| Q3 25 | $-22.2M | $4.9M | ||
| Q2 25 | $-20.7M | $501.0K | ||
| Q1 25 | $-30.3M | $191.0K | ||
| Q4 24 | — | $12.9M | ||
| Q3 24 | $-27.9M | $2.3M | ||
| Q2 24 | $-39.0M | $7.0M | ||
| Q1 24 | $-62.5M | $4.2M | ||
| Q4 23 | $-14.1M | $2.9M |
自由现金流LABSACH
| Q3 25 | $-23.1M | — | ||
| Q2 25 | $-22.6M | — | ||
| Q1 25 | $-35.3M | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $-30.1M | — | ||
| Q2 24 | $-41.0M | — | ||
| Q1 24 | $-63.3M | — | ||
| Q4 23 | $-14.1M | — |
自由现金流率LABSACH
| Q3 25 | -118.1% | — | ||
| Q2 25 | -103.6% | — | ||
| Q1 25 | -86.6% | — | ||
| Q4 24 | — | — | ||
| Q3 24 | -136.4% | — | ||
| Q2 24 | -182.2% | — | ||
| Q1 24 | -138.9% | — | ||
| Q4 23 | -50.2% | — |
资本支出强度LABSACH
| Q3 25 | 4.5% | — | ||
| Q2 25 | 8.7% | — | ||
| Q1 25 | 12.4% | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 10.2% | — | ||
| Q2 24 | 8.6% | — | ||
| Q1 24 | 1.7% | — | ||
| Q4 23 | 0.3% | — |
现金转化率LABSACH
| Q3 25 | — | 4.95× | ||
| Q2 25 | — | 0.27× | ||
| Q1 25 | — | 0.21× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | 0.90× | ||
| Q4 23 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
LAB
| Consumables | $8.7M | 45% |
| Services And Other Revenue | $5.8M | 29% |
| Instruments | $5.1M | 26% |
SACH
暂无分部数据
